Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
RemeGen Co., Ltd
{{company.company_channel.channel_name}}
Media Room
Latest
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
2022-09-19 21:00
Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives
2022-07-25 11:00
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting
2022-05-24 10:27
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
2022-01-26 10:52
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
2022-01-25 09:00
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021
2021-12-15 09:35
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment
2021-12-03 13:45
1
2